Synergistic activation of human natural killer cell cytotoxicity by histamine and interleukin-2
- PMID: 2150668
- DOI: 10.1159/000235169
Synergistic activation of human natural killer cell cytotoxicity by histamine and interleukin-2
Abstract
Interleukin-2 (IL-2) is recognized as a major activating signal for human natural killer (NK) cells. The presence of monocytes alters NK cell responsiveness to IL-2. Thus, while IL-2 effectively augments NK cell cytotoxicity (NKCC) in monocyte-depleted NK effector cells, it is relatively ineffective or even suppressive for NK cells in monocyte-containing, NK-cell-enriched mononuclear cell fractions. Here we report that concomitant treatment with IL-2 and the biogenic amine histamine synergistically augmented NKCC against K562 and Daudi target cells of CD3-/CD16+ human NK cells in the presence but not in the absence of monocytes. Addition of peripheral-blood monocytes, recovered by countercurrent centrifugal elutriation, to purified NK cells abrogated IL-2 induced NK cell activation, reconstituted the synergistic, NK-activating effects of histamine and IL-2, and strongly reduced baseline NKCC. The effects of histamine on baseline NKCC and on NK cell responsiveness to IL-2 were related to counteraction of monocyte-mediated NK cell suppression. By contrast, histamine did not affect baseline or IL-2-induced NKCC in mixtures of NK cells and monocytes when the latter cells were recovered after adherence. The effect of histamine on NK cell responsiveness to IL-2 was mediated by H2-type histamine receptors, as judged by mimicry exerted by the specific H2 receptor agonist dimaprit, but not by an H2-receptor-inactive derivative of this compound, N-methyldimaprit, and blocking by the H2 receptor antagonist ranitidine. Experiments in which monocytes and nonadherent NK cells were separately pretreated with ranitidine prior to histamine treatment suggested that NK-regulatory effects of histamine were mediated by H2 receptors on monocytes. Our data suggest that histamine may provide an important signal in the regulation of NK cell responsiveness to IL-2.
Similar articles
-
Monocyte-induced down-modulation of CD16 and CD56 antigens on human natural killer cells and its regulation by histamine H2-receptors.Cell Immunol. 1991 Nov;138(1):44-54. doi: 10.1016/0008-8749(91)90131-t. Cell Immunol. 1991. PMID: 1717164
-
Cell-to-cell mediated inhibition of natural killer cell proliferation by monocytes and its regulation by histamine H2-receptors.Scand J Immunol. 1991 Dec;34(6):741-52. doi: 10.1111/j.1365-3083.1991.tb01599.x. Scand J Immunol. 1991. PMID: 1836274
-
A cell-to-cell mediated interaction involving monocytes and non-T/CD16+ natural killer (NK) cells is required for histamine H2-receptor-mediated NK-cell activation.Scand J Immunol. 1990 May;31(5):631-44. doi: 10.1111/j.1365-3083.1990.tb02814.x. Scand J Immunol. 1990. PMID: 1693229
-
Histamine and cytokine therapy.Acta Oncol. 1998;37(4):347-53. doi: 10.1080/028418698430566. Acta Oncol. 1998. PMID: 9743456 Review.
-
Cancer immunotherapy with natural killer cells.Semin Oncol. 2002 Jun;29(3 Suppl 7):27-30. doi: 10.1053/sonc.2002.33079. Semin Oncol. 2002. PMID: 12068385 Review.
Cited by
-
Interleukin-2 and histamine in combination inhibit tumour growth and angiogenesis in malignant glioma.Br J Cancer. 2000 Sep;83(6):826-32. doi: 10.1054/bjoc.2000.1354. Br J Cancer. 2000. PMID: 10952789 Free PMC article.
-
Natural killer cells modulation in hematological malignancies.Front Immunol. 2013 Dec 19;4:459. doi: 10.3389/fimmu.2013.00459. Front Immunol. 2013. PMID: 24391641 Free PMC article.
-
Role of natural killer cell subsets and natural cytotoxicity receptors for the outcome of immunotherapy in acute myeloid leukemia.Oncoimmunology. 2015 May 5;5(1):e1041701. doi: 10.1080/2162402X.2015.1041701. eCollection 2016. Oncoimmunology. 2015. PMID: 26942055 Free PMC article.
-
Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer.Drugs. 1993 Sep;46(3):446-514. doi: 10.2165/00003495-199346030-00009. Drugs. 1993. PMID: 7693434 Review.
-
Two randomised phase II trials of subcutaneous interleukin-2 and histamine dihydrochloride in patients with metastatic renal cell carcinoma.Br J Cancer. 2005 Oct 3;93(7):757-62. doi: 10.1038/sj.bjc.6602768. Br J Cancer. 2005. PMID: 16136045 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources